Johnson Pharmacare Limited announced its unaudited standalone financial results for the quarter ended 31st December, 2025, during a board meeting held on 14th February, 2026. The pharmaceutical company continues to face operational challenges with no revenue generation and mounting losses.

Financial Performance Overview

The company's financial performance for Q3 FY26 shows continued losses across all operational metrics. Johnson Pharmacare reported zero revenue from operations for the current quarter, consistent with previous quarters.

Expense Analysis

The company's expense structure for Q3 FY26 reveals significant increases across multiple categories compared to the previous quarter.

Finance costs emerged as the largest expense component at 4.01 lakhs for the current quarter, while other expenses contributed 2.18 lakhs. Employee benefits expense decreased to 0.21 lakhs from 0.30 lakhs in the previous quarter.

Nine-Month Performance

For the nine months ended 31st December, 2025, Johnson Pharmacare recorded a cumulative loss of 12.34 lakhs compared to 7.06 lakhs in the corresponding period of the previous year. Total expenses for the nine-month period stood at 12.34 lakhs, with other expenses accounting for 7.25 lakhs, finance costs at 4.28 lakhs, and employee benefits at 0.81 lakhs.

Share Capital and Earnings Per Share

The company maintains a paid-up equity share capital of 5,500.00 lakhs with a face value of Re. 1 per share. Basic and diluted earnings per share for continuing operations stood at (0.00) for Q3 FY26, Q2 FY26, and Q3 FY25.

Regulatory Compliance

The board also addressed compliance with Regulation 32 of SEBI (LODR) Regulations, 2015, confirming its non-applicability as the company has not issued shares through rights issue, preferential allotment, or any other issue during the quarter ended 31st December, 2025. The results were approved during a board meeting held at the company's registered office in Ahmedabad, Gujarat, under the chairmanship of Additional Director Rajender Parsad.

Johnson Pharmacare Limited announced the appointment of a new Additional Executive Director following a board meeting held on February 09, 2026. The pharmaceutical company's board approved the appointment in compliance with regulatory requirements under SEBI listing obligations.

Board Meeting Details

The board meeting was conducted on Monday, February 09, 2026, with specific timing and agenda focused on directorial appointments.

New Director Appointment

The board approved the appointment of Mr. Umesh Kumar as Additional Executive Director with immediate effect. The appointment was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance

As part of the appointment process, Mr. Umesh Kumar submitted a declaration of non-debarment as required under SEBI regulations. The declaration confirms his eligibility to hold the directorial position and states that he is not related to existing Directors or Key Managerial Personnel of the Company.

Key compliance confirmations include:

• Not debarred from accessing the Capital Market
• No orders passed by SEBI or other authorities debarring him from holding director positions
• Full compliance with SEBI (LODR) 2015 requirements
• Declaration signed on February 09, 2026, from Haryana

Company Information

Johnson Pharmacare Limited operates from its registered office located at Office No. 4-D, Fourth Floor Vardan Tower, Lakhudi Circle, Near Sardar Patel Stadium, Navrangpura, Ahmedabad, Gujarat. The company trades under scrip code 532154 on BSE Limited with ISIN INE560F01022.

The appointment was signed and approved by Rajender Parsad, Additional Director (DIN: 10871533), on behalf of the Board of Directors of Johnson Pharmacare Limited. The company's CIN is L51100GJ1994PLC022388.